# Breast Cancer Research Foundation
**Type:** Institutions
**Canonical URL:** https://scholariq.org/institutions/breast-cancer-research-foundation/
## Facts
| Field | Value |
| --- | --- |
| Avg h-index | 74.2 |
| Citations | 705,612 |
| City | New York |
| Country | US |
| Description | Breast Cancer Research Foundation is a research organisation in New York, US. OpenAlex records 3,532 works and 705,612 citations for it. 1,149 researchers list it as their most recent affiliation. |
| Homepage | http://www.bcrfcure.org/ |
| OpenAlex ID | https://openalex.org/I196764719 |
| Region | New York |
| Researchers | 1,149 |
| ROR ID | https://ror.org/0348ff195 |
| Type | nonprofit |
| Wikidata ID | https://www.wikidata.org/wiki/Q7719929 |
| Works | 3,532 |
## University papers
Showing 12 of 55.
- [Adjuvant Trastuzumab in HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-trastuzumab-in-her2-positive-breast-cancer/)
- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [AACR Project GENIE: Powering Precision Medicine through an International Consortium](https://scholariq.org/papers/aacr-project-genie-powering-precision-medicine-through-an-international/)
- [The landscape of cancer genes and mutational processes in breast cancer](https://scholariq.org/papers/the-landscape-of-cancer-genes-and-mutational-processes-in-breast-cancer/)
- [STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints](https://scholariq.org/papers/adaptive-resistance-to-therapeutic-pd-1-blockade-is-associated-with-upregulation/)
- [Immune-related adverse events of checkpoint inhibitors](https://scholariq.org/papers/immune-related-adverse-events-of-checkpoint-inhibitors/)
- [Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors](https://scholariq.org/papers/activation-of-the-pd-1-pathway-contributes-to-immune-escape-in-egfr-driven-lung/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas](https://scholariq.org/papers/sox2-is-an-amplified-lineage-survival-oncogene-in-lung-and-esophageal-squamous/)
- [Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
## University top topics
Showing 8 of 25.
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.